BioCentury | Jul 20, 2018
Company News

U of Helsinki grants Herantis rights to a non-invasive CDNF approach

...for non-invasive delivery of cerebral dopamine neurotrophic factor (CDNF) based on a modification of natural CDNF...
...natural CDNF in a Phase I/II trial at three European university hospitals. In the study, CDNF...
...Pharma plc (HSE:HRTIS), Helsinki, Finland Business: Neurology Shannon Lehnbeuter Herantis Pharma plc University of Helsinki Cerebral dopamine neurotrophic factor (CDNF...
Items per page:
1 - 1 of 1